Steven Rosen, based in Cambridge, MA, US, is currently a Interim CEO, TikkunLev Therapeutics, a Gene Therapy Company for Heart Failure Treatment at TikkunLev Therapeutics, bringing experience from previous roles at Wyss Institute at Harvard University, Johnson and Johnson Innovations, Johnson & Johnson and Elucida Oncology, Inc.. Steven Rosen holds a New York University. With a robust skill set that includes Biotechnology, Medical Devices, Healthcare, Lifesciences, Commercialization and more, Steven Rosen contributes valuable insights to the industry. Steven Rosen has 10 emails and 1 mobile phone number on RocketReach.